• G Berrada El Azizi, S Ahid, I Ghanname, A Belaiche, M Hassar, and Y Cherrah.
• Research Team of Pharmacoepidemiology & Pharmacoeconomics, Laboratory of Pharmacology & Toxicology, Faculty of Medicine & Pharmacy, University Mohammed V-Souissi, Rabat, Morocco. berradaghizlane_1@yahoo.com
• Pharmacoepidemiol Drug Saf. 2012 Oct 1; 21 (10): 1067-73.

PurposeIn this study, we analyzed the consumption trends of antihypertensives in Morocco during the 1991-2010 period and the impacts after the institution of Mandatory Health Insurance and the marketing of generic drugs.MethodsWe used sales data from the Moroccan subsidiary of IMS Health "Intercontinental Marketing Service". The consumption volumes were converted into defined daily doses (DDDs).ResultsBetween 1991 and 2010, outpatient consumption of antihypertensives went from 4.37 to 23.14 DDD/1000 inhabitants/day, a 5.30-fold increase. In 2010, calcium channel blockers (CCBs) and angiotensin converting enzyme inhibitors (ACEI) were the most consumed (4.97 DDD/1000 inhabitants/day) for each one, followed by diuretics (4.20 DDD/1000 inhabitants/day). The most consumed products were amlodipine (4.27 DDD/1000 inhabitants/day) followed by ramipril (3.18 DDD/1000 inhabitants /day) and indapamide (1.72 DDD/1000inhabitants/day). Between 1991 and 2010, the consumption of generic antihypertensives went from 2% to 46%.ConclusionAntihypertensive consumption increased between 1991 and 2010. However, despite the increase of generic drugs consumption, the levels of antihypertensive consumption remain lower than the needs of hypertensive patients.Copyright © 2012 John Wiley & Sons, Ltd.

16 keywords...

hide…